Car-T cell therapy: T-immunotherapy application in blood cancer

Considering the unsuccessful results and lack of sustainable efficiency of previous cancer therapies, T-immunotherapy's clinical success has led to a revolution in cancer treatments. Blood cancers, characterized by abnormal blood cells and metastasis, result in severe health issues and cause high mortality rates. Conventional treatments like chemotherapy and radiation often result in poor prognoses due to cancer cell resistance and have a high relapse rate. This paper focuses on how Chimeric Antigen Receptor (CAR)-T cell therapy removes tumor cancerous cells with genetically engineered T-cells. The specific targeting ability of T-cell allows it to overcome the difficulty unresolved by traditional treatments. Despite its significant progress, CAR-T cell therapy also experienced new challenges brought by its specific treatment: cytokine release syndrome and logistical complexities. This paper provides a comprehensive review of T-cell therapy's novel enhancement of blood cancers, including its mechanisms, applications, and side effects after therapy. Various data underline T-cell therapy's potential as a novel cancer treatment, though further research is needed to address its limitations and improve patient outcomes. This research paper provides valuable insights into CAR-T therapy application, minimizing toxicity, and expanding its applicability, offering a reference for future research. Unresolved issues such as managing side effects and improving accessibility continue to be focused for future investigation.